Share on StockTwits

bluebird bio (NASDAQ:BLUE) VP Linda Bain sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $25.11, for a total value of $62,775.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of bluebird bio (NASDAQ:BLUE) traded down 6.72% on Friday, hitting $21.65. The stock had a trading volume of 193,810 shares. bluebird bio has a 52-week low of $17.03 and a 52-week high of $36.25. The stock has a 50-day moving average of $21.63 and a 200-day moving average of $24.72. The company’s market cap is $511.6 million.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.25) by $0.01. The company had revenue of $6.39 million for the quarter, compared to the consensus estimate of $5.59 million. The company’s quarterly revenue was up 7417.6% on a year-over-year basis. On average, analysts predict that bluebird bio will post $-1.52 earnings per share for the current fiscal year.

bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.